Literature DB >> 9373657

Severe and complicated malaria treated with artemisinin, artesunate or artemether in Viet Nam.

V Ha1, N H Nguyen, T B Tran, M C Bui, H P Nguyen, T H Tran, T Q Phan, K Arnold, T H Tran.   

Abstract

One hundred and seventy five Vietnamese adults with severe and complicated malaria admitted to a rural district hospital were entered into an open randomized comparative study to compare 4 treatment regimens based on artemisinin and its derivatives. The median time of defervescence was 48 h (95% confident interval [CI] 38-58 h) in those given intramuscular (i.m.) artemether, 42 h (95% CI 36-48 h) in those given artemisinin suppositories, 36 h (95% CI 30-42 h) in those receiving artesunate (i.m.) and 30 h (95% CI 18-42 h) in those receiving intravenous artesunate (P = 0.13). The respective median parasite clearance times were 30 h (95% CI 26-34 h), 30 h (95% CI 24-36 h), 24 h (95% CI 15-33 h), and 24 h (95% CI 15-33 h) (P = 0.30); the median times for recovery of consciousness were 47 h (95% CI 31-63 h), 24 h (95% CI 18-30 h), 30 h (95% CI 18-42 h), and 24 h (95% CI 4-44 h) (P = 0.18); and the mortality rates were 11.1%, 17.6%, 10.2% and 16.6%, respectively (P = 0.64). There was no significant difference in efficacy between the 4 treatments.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9373657     DOI: 10.1016/s0035-9203(97)90287-x

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  16 in total

1.  Human malaria in immunocompromised mice: new in vivo model for chemotherapy studies.

Authors:  A Moreno; E Badell; N Van Rooijen; P Druilhe
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Artemether for severe malaria.

Authors:  Ekpereonne B Esu; Emmanuel E Effa; Oko N Opie; Martin M Meremikwu
Journal:  Cochrane Database Syst Rev       Date:  2019-06-18

3.  The pharmacokinetic properties of intramuscular artesunate and rectal dihydroartemisinin in uncomplicated falciparum malaria.

Authors:  Kenneth F Ilett; Kevin T Batty; Shane M Powell; Tran Quang Binh; Le Thi Anh Thu; Hoang Lan Phuong; Nguyen Canh Hung; Timothy M E Davis
Journal:  Br J Clin Pharmacol       Date:  2002-01       Impact factor: 4.335

Review 4.  Artemisinin derivatives for treating severe malaria.

Authors:  H M McIntosh; P Olliaro
Journal:  Cochrane Database Syst Rev       Date:  2000

5.  Multiple dose study of interactions between artesunate and artemisinin in healthy volunteers.

Authors:  S Q Zhang; T N Hai; K F Ilett; D X Huong; T M Davis; M Ashton
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

Review 6.  Artemisinins.

Authors:  C J Woodrow; R K Haynes; S Krishna
Journal:  Postgrad Med J       Date:  2005-02       Impact factor: 2.401

7.  Comparative efficacy and safety of the artemisinin derivatives compared to quinine for treating severe malaria in children and adults: A systematic update of literature and network meta-analysis.

Authors:  Nicholas Nyaaba; Nana Efua Andoh; Gordon Amoh; Dominic Selorm Yao Amuzu; Mary Ansong; José M Ordóñez-Mena; Jennifer Hirst
Journal:  PLoS One       Date:  2022-07-20       Impact factor: 3.752

8.  Clinical experience with intravenous quinine, intramuscular artemether and intravenous artesunate for the treatment of severe malaria in Thailand.

Authors:  Srivicha Krudsood; Polrat Wilairatana; Suparp Vannaphan; Sombat Treeprasertsuk; Udomsak Silachamroon; Weerapong Phomrattanaprapin; Victor R Gourdeuk; Gary M Brittenham; Sornchai Looareesuwan
Journal:  Southeast Asian J Trop Med Public Health       Date:  2003-03       Impact factor: 0.267

9.  Intravenous artesunate for severe malaria in travelers, Europe.

Authors:  Thomas Zoller; Thomas Junghanss; Annette Kapaun; Ida Gjorup; Joachim Richter; Mats Hugo-Persson; Kristine Mørch; Behruz Foroutan; Norbert Suttorp; Salih Yürek; Holger Flick
Journal:  Emerg Infect Dis       Date:  2011-05       Impact factor: 6.883

Review 10.  Rectal artemisinins for malaria: a review of efficacy and safety from individual patient data in clinical studies.

Authors:  Melba Gomes; Isabela Ribeiro; Marian Warsame; Harin Karunajeewa; Max Petzold
Journal:  BMC Infect Dis       Date:  2008-03-28       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.